Using Biosimulation to Inform COVID-19 Vaccine Development

Pharma Tech Outlook: Pharma Tech Magazine

Using Biosimulation to Inform COVID-19 Vaccine Development

Stacey Smith, Pharma Tech Outlook | Wednesday, March 02, 2022

Biosimulation can make sure that every individual patient gets the best dosage of a COVID-19 vaccine.

FREMONT, CA: The use of biosimulation has heightened lately in drug and discovery applications like lead identification and optimization, pre-clinical testing of novel drugs, and target identification and validation. This factor may accelerate the growth prospects of the global biosimulation industry significantly during the assessment period. Heightening attention to improving drug development and discovery, increasing emphasis on enhancing model engineering factors, and growing adoption of artificial intelligence (AI) are the factors that bring profitable growth for the biosimulation industry.

Drug development can be a costly and tedious process. Add in the urgency of the global COVID-19 pandemic, and pharma has a recipe for frustration. Biosimulation that is leveraging computers to simulate drug response in humans. This can accelerate the process, which hopes to gain a platform targeted at COVID-19 vaccine development. The COVID-19 quantitative systems pharmacology platform is a new biosimulation platform for COVID-19 vaccines that uses its immunogenicity and immuno-oncology QSP. In an initiative to boost the development of COVID-19 vaccines and therapies, scientists should quickly answer essential questions and work on several developmental stages simultaneously. Moreover, large pharmaceutical and biotechnology firms, nonprofits, and governments require to work together to beat COVID-19.

One way to gear things up is to use biosimulation -- computer-based modeling of human biology, drug behavior, and disease. For COVID-19, these risks are mounted by parallel developments within accelerated timelines. In usually vaccine development, doses are carefully chosen before manufacturing process development. With a similar product, the dosage is not validated to the extent that it would usually be. There is a chance that the dose at which the manufacturing operation for a drug candidate is set up will fail in early development or not be approved.

Biosimulation can assist get it right the first time around. Getting the optimal dose for safety and efficacy right the first time can inform the manufacturing operation, including validation, testing, and stability procedures, and assist manufacturers to invest in the right manufacturing for the suitable vaccine. Biosimulation platforms can help enterprises make informed decisions about vaccine candidates across several patient populations. Trial and error, particularly for determining dosage, is too costly and timely. Technology platforms like biosimulation can help stakeholders answer what-if questions that may not be possible in real-world situations.

Weekly Brief

Read Also